Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia

The 7 + 3 regimen is the front-line induction chemotherapy in patients with newly diagnosed acute myeloid leukemia, with a response rate of 60-80%. But it’s not suitable for all patients especially old/unfit patients because of a higher treatment related toxicity. Therefore, safer and more effective...

Full description

Bibliographic Details
Main Authors: Jun-Feng Zhu, Hai-Ping Dai, Qian-Qian Zhang, Jia Yin, Zheng Li, Qin-Ya Cui, Xiao-Peng Tian, Si-Ning Liu, Zheng-Ming Jin, Xia-Ming Zhu, De-Pei Wu, Xiao-Wen Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
induction chemotherapy
decitabine
HAAG
acute myeloid leukemia
efficacy and safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.998884/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.998884/full

Similar Items